456 SOMATOSENSORY PROCESSING IN PINK1 (PARK6) AND PARKIN MUTATION CARRIERS: ITS POTENTIAL ROLE IN PARKINSON'S DISEASE

2007 ◽  
Vol 11 (S1) ◽  
pp. S202-S202
Author(s):  
J. Ludwig ◽  
F. Lienau ◽  
R. Maag ◽  
J.M. Hagenah ◽  
G. Deuschl ◽  
...  
2010 ◽  
Vol 48 (2) ◽  
pp. 467-476 ◽  
Author(s):  
Rolf Verleger ◽  
Johann Hagenah ◽  
Manuel Weiß ◽  
Thomas Ewers ◽  
Ilse Heberlein ◽  
...  

2020 ◽  
Vol 25 (42) ◽  
pp. 4510-4522 ◽  
Author(s):  
Biancamaria Longoni ◽  
Irene Fasciani ◽  
Shivakumar Kolachalam ◽  
Ilaria Pietrantoni ◽  
Francesco Marampon ◽  
...  

: Exosomes are extracellular vesicles produced by eukaryotic cells that are also found in most biological fluids and tissues. While they were initially thought to act as compartments for removal of cellular debris, they are now recognized as important tools for cell-to-cell communication and for the transfer of pathogens between the cells. They have attracted particular interest in neurodegenerative diseases for their potential role in transferring prion-like proteins between neurons, and in Parkinson’s disease (PD), they have been shown to spread oligomers of α-synuclein in the brain accelerating the progression of this pathology. A potential neuroprotective role of exosomes has also been equally proposed in PD as they could limit the toxicity of α-synuclein by clearing them out of the cells. Exosomes have also attracted considerable attention for use as drug vehicles. Being nonimmunogenic in nature, they provide an unprecedented opportunity to enhance the delivery of incorporated drugs to target cells. In this review, we discuss current knowledge about the potential neurotoxic and neuroprotective role of exosomes and their potential application as drug delivery systems in PD.


Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 754
Author(s):  
Giulia Gaggi ◽  
Andrea Di Credico ◽  
Pascal Izzicupo ◽  
Giovanni Iannetti ◽  
Angela Di Baldassarre ◽  
...  

Parkinson’s disease (PD) is one of the most common neurodegenerative disease characterized by a specific and progressive loss of dopaminergic (DA) neurons and dopamine, causing motor dysfunctions and impaired movements. Unfortunately, available therapies can partially treat the motor symptoms, but they have no effect on non-motor features. In addition, the therapeutic effect reduces gradually, and the prolonged use of drugs leads to a significative increase in the number of adverse events. For these reasons, an alternative approach that allows the replacement or the improved survival of DA neurons is very appealing for the treatment of PD patients and recently the first human clinical trials for DA neurons replacement have been set up. Here, we review the role of chemical and biological molecules that are involved in the development, survival and differentiation of DA neurons. In particular, we review the chemical small molecules used to differentiate different type of stem cells into DA neurons with high efficiency; the role of microRNAs and long non-coding RNAs both in DA neurons development/survival as far as in the pathogenesis of PD; and, finally, we dissect the potential role of exosomes carrying biological molecules as treatment of PD.


RSC Advances ◽  
2015 ◽  
Vol 5 (95) ◽  
pp. 77706-77715 ◽  
Author(s):  
Supinder Kaur ◽  
Aamir Nazir

Studies employing transgenicC. elegansmodel show that trehalose, a protein stabilizer, alleviates manifestations associated with Parkinson's diseaseviaits inherent activity and through induction of autophagic machinery.


2009 ◽  
Vol 256 (7) ◽  
pp. 1192-1194 ◽  
Author(s):  
Susanne Hertel ◽  
Andreas Sprenger ◽  
Christine Klein ◽  
Detlef Kömpf ◽  
Christoph Helmchen ◽  
...  

2021 ◽  
Vol 196 ◽  
pp. 101890 ◽  
Author(s):  
Laura Mahoney-Sánchez ◽  
Hind Bouchaoui ◽  
Scott Ayton ◽  
David Devos ◽  
James A. Duce ◽  
...  

2005 ◽  
Vol 58 (3) ◽  
pp. 411-422 ◽  
Author(s):  
Peter P. Pramstaller ◽  
Michael G. Schlossmacher ◽  
Thomas S. Jacques ◽  
Francesco Scaravilli ◽  
Cordula Eskelson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document